Validation of HB-EGF and amphiregulin as targets for human cancer therapy

Biochemical and Biophysical Research Communications

Volumn 365, Issue 3, 2008, Pages 555-561

  Yotsumoto, Fusanori ^a   Yagi, Hiroshi ^b   Suzuki, Satoshi O ^b   Oki, Eiji ^b   Tsujioka, Hiroshi ^a   Hachisuga, Touru ^c   Sonoda, Kenzo ^b   Kawarabayashi, Tatsuhiko ^a   Mekada, Eisuke ^d   Miyamoto, Shingo ^a  

^a FUKUOKA UNIVERSITY   (Japan)

^b KYUSHU UNIVERSITY   (Japan)

^c UNIVERSITY OF OCCUPATIONAL AND ENVIRONMENTAL HEALTH   (Japan)

^d OSAKA UNIVERSITY   (Japan)

Author keywords

Amphiregulin; EGFR; HB EGF; Human cancer; Targeting therapy

Indexed keywords

AMPHIREGULIN; HEPARIN BINDING EPIDERMAL GROWTH FACTOR; LIGAND; SMALL INTERFERING RNA;

APOPTOSIS; ARTICLE; BILE DUCT CARCINOMA; BREAST CANCER; CANCER CELL; CANCER THERAPY; CELL ACTIVATION; COLON CANCER; CONTROLLED STUDY; DISEASE COURSE; DRUG TARGETING; GLIOBLASTOMA; HUMAN; HUMAN CELL; IN VITRO STUDY; KIDNEY CARCINOMA; LUNG CANCER; MELANOMA; OVARY CANCER; PANCREAS CANCER; PRIORITY JOURNAL; PROSTATE CANCER; PROTEIN EXPRESSION; STOMACH CANCER;

CELL LINE, TUMOR; FEMALE; GLYCOPROTEINS; HUMANS; INTERCELLULAR SIGNALING PEPTIDES AND PROTEINS; LIGANDS; MALE; NEOPLASMS; RECEPTOR, EPIDERMAL GROWTH FACTOR; RECEPTOR, ERBB-2; RNA, MESSENGER; RNA, SMALL INTERFERING; SIGNAL TRANSDUCTION;

EID: 36549072385     PISSN: 0006291X     EISSN: 10902104     Source Type: Journal    
DOI: 10.1016/j.bbrc.2007.11.015     Document Type: Article

References (34)

1. Citri A., and Yarden Y. EGF-ERBB signaling: towards the systems level. Nat. Rev. Mol. Cell Biol. 7 (2006) 505-516
2. Hynes N.E., and Lane H.A. ERBB receptors and cancer: the complexity of targeted inhibitors. Nat. Rev. Cancer 5 (2005) 341-354
3. Salomon D.S., Brandt R., Ciardiello F., and Normanno N. Epidermal growth factor-related peptides and their receptors in human malignancies. Crit. Rev. Oncol. Hematol. 19 (1995) 183-232
4. Baselga J., and Artaga C.L. Critical update and emerging trends in epidermal growth factor receptor targeting in cancer. J. Clin. Oncol. 23 (2005) 2445-2459
5. Roch-Lima C.M., Soares H.P., Raez L.E., and Singal R. EGFR targeting of solid tumors. Cancer Control 14 (2007) 295-304
6. Riese II D.J., and Stern D.F. Specificity within the EGF family/ErbB receptor family signaling network. BioEssays 20 (1998) 41-48
7. Harris R.C., Chung E., and Coffey R.J. EGF receptor ligands. Exp. Cell Res. 284 (2003) 2-13
8. Miyamoto S., Hirata M., Yamazaki A., Kageyama T., Hasuwa H., Mizushima H., Tanaka Y., Yagi H., Sonoda K., Kai M., Kanoh H., Nakano H., and Mekada E. Heparin-binding EGF-like growth factor is a promising target for ovarian cancer therapy. Cancer Res. 64 (2004) 5720-5727
9. Uchida T., Pappenheimer Jr. A.M., and Greany R. Diphtheria toxin and related proteins. J. Biol. Chem. 248 (1973) 3838-3844
10. Tanaka Y., Miyamoto S., Suzuki S.O., Oki E., Yagi H., Sonoda K., Yamazaki A., Mizushima H., Maehara Y., Mekada E., and Nakano H. Clinical significance of heparin-binding growth factor-like growth factor and a disintegrin and metalloprotease 17 expression in human ovarian cancer. Clin. Cancer Res. 11 (2005) 4783-4792
11. Higashiyama S., Iwamoto R., Goishi K., Raab G., Taniguchi N., Klagsbrun M., and Mekada E. The membrane protein CD9/DRAP 27 potentiates the juxtacrine growth factor activity of the membrane-anchored heparin-binding EGF-like growth factor. J. Cell Biol. 128 (1995) 929-938
12. Yagi H., Miyamoto S., Tanaka Y., Sonoda K., Kobayashi H., Kishikawa T., Iwamoto R., Mekada E., and Nakano H. Clinical significance of heparin-binding epidermal growth factor-like growth factor in peritoneal fluid of ovarian cancer. Br. J. Cancer 92 (2005) 1737-1745
13. Schelfhout V.R.J., Coene E.D., Delaey B., Waeytens A.A.T., Rycke L.D., Deleu M., and De Potter C.R. The role of heregulin-α as a motility factor and amphiregulin as a growth factor in wound healing. J. Pathol. 198 (2002) 523-533
14. Shirakata Y., Kimura R., Nanba D., Iwamoto R., Tokumaru S., Morimoto C., Yokota K., Nakamura M., Sayama K., Mekada E., Higahiyama S., and Hashimoto K. Heparin-binding EGF-like growth factor accelerates keratinocyte migration and skin wound healing. J. Cell Sci. 118 (2005) 2363-2370
15. Lee D.S., Yanagimoto-Ueta Y., and Suzuki H. Expression of amphiregulin during the pre- and post- implantation period in the mouse reproductive tract. J. Reprod. Dev. 52 (2006) 781-787
16. Barnard J.A., Beauchamp R.D., Russell W.E., Dubois R.N., and Coffey R.J. Epidermal growth factor-related peptides and their relevance to gastrointestinal pathophysiology. Gastroenterology 108 (1995) 564-580
17. McCarthy S.A., Samuels M.L., Pritchard C.A., Abraham J.A., and McMahon M. Rapid induction of heparin-binding epidermal growth factor/diphtheria toxin receptor expression by Raf and Ras oncogenes. Genes Dev. 9 (1995) 1953-1964
18. Gangarosa L.M., Sizemore N., Graves-Deal R., Oldham S.M., Der C.J., and Robert J.C. A Raf-independent epidermal growth factor receptor autocrine loop is necessary for Ras transformation of Rat intestinal epithelial cells. J. Biol. Chem. 272 (1997) 18926-18931
19. Schulze A., Lehmann K., Jefferies H.B.J., McMahon M., and Downward J. Analysis of the transcriptional program induced by Raf in epithelial cells. Genes Dev. 15 (2001) 981-994
20. Robert P.J., and Der C.J. Targeting the Raf-MEK-ERK mitogen-activated protein kinase cascade for the treatment of cancer. Oncogene 26 (2007) 3291-3310
21. Sibilia M., Fleischmann A., Behrens A., Stingl L., Carroll J., Watt F.M., Schlessinger J., and Wagner E.F. The EGF receptor provides an essential survival signal for SOS-dependent skin tumor development. Cell 102 (2000) 211-220
22. Iwamoto R., Yamazaki S., Asakura M., Takashima S., Hasuwa H., Miyado K., Adachi S., Kitakaze M., Hashimoto K., Raab G., Nanba D., Higashiyama S., Hori M., Klagsbrun M., and Mekada E. Heparin-binding EGF-like growth factor and ErbB signaling is essential for heart function. Proc. Natl. Acad. Sci. USA 100 (2003) 3221-3226
23. Mitchell C., Nivison M., Jackson L.F., Fox R., Lee D.C., Campbell J.S., and Fausto N. Heparin-binding epidermal growth factor-like growth factor links hepatocyte priming with cell cycle progression during liver regeneration. J. Biol. Chem. 280 (2005) 2562-2568
24. Luetteke N.C., Qiu T.H., Fenton S.E., Troyer K.L., Riedel R.F., Chang A., and Lee D.C. Targeted inactivation of the EGF and amphiregulin genes reveals distinct roles for EGF receptor ligands in mouse mammary gland development. Development 126 (1999) 2739-2750
25. Berasain C., Garcia-Trevijano E.R., Castillo J., Erroba E., Santamaria M., Lee D.C., Prieto J., and Avila M.A. Novel role for amphiregulin in protection from liver injury. J. Biol. Chem. 280 (2005) 19012-19020
26. Troyer K.L., Luetteke N.C., Saxon M.L., Qiu T.H., Xian C.J., and Lee D.C. Growth retardation, duodenal lesions, and aberrant ileum architecture in triple null mice lacking EGF, amphiregulin, and TGF-α. Gastroenterology 121 (2001) 68-78
27. Wagner M., Weber C.K., Bressau F., Greten F.R., Stagge V., Ebert M., Leach S.D., Adler G., and Schmid R.M. Transgenic overexpression of amphiregulin induces a mitogenic response selectively in pancreatic duct cells. Gastroenterology 122 (2002) 1898-1912
28. Luetteke N.C., Qiu T.H., Peiffer R.L., Oliver P., Smithies O., and Lee D.C. TGFα deficiency results in hair follicle and eye abnormalities in targeted and waved-1 mice. Cell 73 (1993) 263-278
29. Mann G.B., Fowler K.J., Gabriel A., Nice E.C., Williams R.L., and Dunn A.R. Mice with a null mutation of the TGFα gene have abnormal skin architecture, wavy hair, and curly whiskers and often develop corneal inflammation. Cell 73 (1993) 249-261
30. Jackson L.F., Qui T.H., Sunnarborg S.W., Chang A., Zhang C., Patterson C., and Lee D.C. Defective valvulogenesis in HB-EGF and TACE-null mice is associated with aberrant BMP signaling. EMBO J. 22 (2003) 2704-2716
31. Lee D., Pearsall R.S., Das S., Dey S.K., Godfrey V.L., and Threadgill D.W. Epiregulin is not essential for development of intestinal tumors but is required for protection from intestinal damage. Mol. Cell. Biol. 24 (2004) 8907-8916
32. Mak K.K.L., and Chan S.Y. Epidermal growth factor as a biologic switch in hair growth cycle. J. Biol. Chem. 278 (2003) 26120-26126
33. Schneider M.R., Dahlhoff M., Herbach N., Renner-Mueller I., Dalke C., Puk O., Graw J., Wanke R., and Wolf E. Betacellulin overexpression in transgenic mice causes disproportionate growth, pulmonary hemorrhage syndrome, and complex eye pathology. Endocrinology 146 (2005) 5237-5246
34. Morigillo F., and Lee H.Y. Resistance to epidermal growth factor receptor-targeted therapy. Drug Resist. Updat. 8 (2005) 298-310